Surgical Oncology Insight最新文献

{"title":"Malignant bowel obstruction: Historical lessons, current trends, and future directions","authors":"Mohammad S. Farooq ,&nbsp;Giorgos C. Karakousis ,&nbsp;Robert S. Krouse","doi":"10.1016/j.soi.2024.100046","DOIUrl":"https://doi.org/10.1016/j.soi.2024.100046","url":null,"abstract":"<div><p>Malignant bowel obstruction (MBO) is defined as a mechanical/functional/radiologic obstruction of the gastrointestinal tract beyond the Ligament of Treitz in the presence of a known primary or metastatic abdominopelvic malignancy. Though numerous retrospective studies have been conducted on the outcomes of various treatment modalities, there is a tremendous heterogeneity of MBO definitions, clinical presentations, and offered treatments. Few prospective studies or randomized trials exist, making it difficult to ascertain generalizable data and develop applicable clinical guidelines. In this review, a systematic computerized search was conducted on PubMed for high quality data on MBO epidemiology, pathophysiology, and treatment modalities, with a particular focus on comprehensive systematic literature reviews. The current standard of care for medical, surgical, and endoscopic treatment of MBO was discussed in detail. Historical data was contextualized and the latest findings of the first randomized-controlled clinical trial (SWOG S1316) studying surgical vs. non-surgical treatment of MBO was critically appraised. These findings give insight on how to optimize future trial design, measure comprehensive quality of life outcomes, and develop clinical practice guidelines in line with patient-specific goals of treatment.</p></div>","PeriodicalId":101191,"journal":{"name":"Surgical Oncology Insight","volume":"1 2","pages":"Article 100046"},"PeriodicalIF":0.0,"publicationDate":"2024-04-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2950247024000550/pdfft?md5=1fa59ab0c5d4b7d97582dd3d90b34884&pid=1-s2.0-S2950247024000550-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140558080","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Intra-pleural and intra-peritoneal tocilizumab therapy for managing malignant pleural effusions and ascites: The Regional Immuno-Oncology Trial (RIOT)−2 study protocol","authors":"Hyun Park ,&nbsp;Catherine Lewis ,&nbsp;Neda Dadgar ,&nbsp;Christopher Sherry ,&nbsp;Shelly Evans ,&nbsp;Staci Ziobert ,&nbsp;Ashten Omstead ,&nbsp;Ali Zaidi ,&nbsp;Kunhong Xiao ,&nbsp;Sohini Ghosh ,&nbsp;David L. Bartlett ,&nbsp;Albert Donnenberg ,&nbsp;Vera Donnenberg ,&nbsp;Patrick L. Wagner","doi":"10.1016/j.soi.2024.100045","DOIUrl":"https://doi.org/10.1016/j.soi.2024.100045","url":null,"abstract":"<div><h3>Background</h3><p>Malignant pleural effusions (MPE) and malignant ascites (MA) are serious complications of advanced cancer, marked by debilitating symptoms and limited treatment options. Based on a wealth of previous literature implicating the cytokine IL-6 as a central mediator in the pathogenesis of MPE and MA, the Regional Immuno-Oncology Trial 2 (RIOT-2) clinical protocol was developed to explore intra-cavitary delivery of tocilizumab, an IL-6 receptor antagonist, as treatment for these conditions.</p></div><div><h3>Methods</h3><p>This phase I clinical trial (NCT 06016179) is being conducted to assess the safety and pharmacokinetics of intra-cavitary tocilizumab administration to patients with MPE and MA. Eligible patients are those with pleural effusion or peritoneal ascites due to metastatic cancer who are scheduled to undergo standard-of-care catheter placement for pleural or peritoneal drainage. Following catheter placement, patients will receive a starting dose of tocilizumab 0.5 µg/mL via intra-pleural or intra-peritoneal implantable catheters. Weekly escalating doses of tocilizumab will be given over four weeks. Primary endpoints are frequency and type of adverse events, while secondary endpoints include pharmacokinetic and immunological parameters. This single-center study will proceed until 12 patients have been treated.</p></div><div><h3>Discussion</h3><p>Inhibition of the IL-6 signaling pathway with tocilizumab is hypothesized to be a rational mitigating treatment strategy for the maladaptive intra-cavitary immune environment in patients with MPE and MA. The RIOT-2 study aims to assess the safety of intra-cavitary tocilizumab therapy, administered via indwelling catheters. Pharmacologic and translational immunologic findings generated by this study could pave the way for future research into clinical applications of intra-cavitary immunotherapy.</p></div><div><h3>Trial registration</h3><p>The trial is registered at ClinicalTrials.gov; NCT06016179 (registered on August 29th, 2023).</p></div>","PeriodicalId":101191,"journal":{"name":"Surgical Oncology Insight","volume":"1 2","pages":"Article 100045"},"PeriodicalIF":0.0,"publicationDate":"2024-04-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2950247024000549/pdfft?md5=e1559fabef892cf19d198e75d0644760&pid=1-s2.0-S2950247024000549-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140540482","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Intra-tumoral immunomodulatory therapy for advanced abdominal cancers using lipopolysaccharide: The Regional Immuno-Oncology Ttrial-1 (RIOT-1) protocol (NCT05751837)","authors":"Catherine Lewis ,&nbsp;Neda Dadgar ,&nbsp;Mehrdokht Najafi ,&nbsp;Hyun Park ,&nbsp;Christopher Sherry ,&nbsp;Alyssa Lucas ,&nbsp;Ali Zaidi ,&nbsp;Kunhong Xiao ,&nbsp;Ashten Omstead ,&nbsp;Albert Donnenberg ,&nbsp;David L. Bartlett ,&nbsp;Vera Donnenberg ,&nbsp;Patrick L. Wagner","doi":"10.1016/j.soi.2024.100042","DOIUrl":"https://doi.org/10.1016/j.soi.2024.100042","url":null,"abstract":"<div><h3>Background</h3><p>Intra-tumoral immunotherapy has shown potential in treating advanced cancers. Delivery challenges have limited exploration of these modalities in intra-abdominal tumors. In this study, we explore the safety of injecting intra-abdominal tumors with lipopolysaccharide (LPS) from <em>Escherichia coli</em> 0113. This agonist of toll-like receptor 4 (TLR4) holds promise as an agent to enhance the anti-tumor immune response within the tumor microenvironment.</p></div><div><h3>Methods</h3><p>This Phase I study will recruit adult patients with peritoneal metastases from gastrointestinal primary malignancies who have at least two suitable intra-abdominal soft tissue tumors for injection. LPS will be administered as a single 1 μg dose during diagnostic laparoscopy in patients in whom a subsequent interval laparotomy is planned. A control injection of saline will be injected into a second lesion. Primary outcome is safety, with secondary outcomes being biomarkers of the tumor immune microenvironment in pre- and post-treatment biopsies.</p></div><div><h3>Results</h3><p>The primary endpoint is to determine the safety (frequency and nature of adverse events) following intra-tumoral LPS injection. Adverse events will be classified using Common Terminology Criteria for Adverse Events. Secondary endpoints include cellular and molecular biomarkers of immune response. The study will proceed until twelve patients have completed the protocol.</p></div><div><h3>Discussion</h3><p>Patients undergoing standard-of-care laparoscopy in preparation for interval cytoreductive surgery may be ideal candidates for intra-tumoral immunotherapy. This study seeks to establish the safety of using <em>E. coli</em> LPS for injection into intra-abdominal tumors and to establish precedent for interval tumor immune microenvironment assessment as a window-of-opportunity concept in the context of abdominal metastatic disease.</p></div><div><h3>Trial Registration</h3><p>The trial is registered at Clinical Trials.gov; NCT05751837 (registered February 28th, 2023).</p></div>","PeriodicalId":101191,"journal":{"name":"Surgical Oncology Insight","volume":"1 2","pages":"Article 100042"},"PeriodicalIF":0.0,"publicationDate":"2024-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2950247024000513/pdfft?md5=ee1f05eb1c690b51594ce75e285671c4&pid=1-s2.0-S2950247024000513-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140342409","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessing the OPRA trial for surgical oncologists: Safety and feasibility of a total neoadjuvant therapy approach in patients with rectal cancer","authors":"Wini Zambare ,&nbsp;Joao Miranda ,&nbsp;Natally Horvat ,&nbsp;J. Joshua Smith","doi":"10.1016/j.soi.2024.100043","DOIUrl":"10.1016/j.soi.2024.100043","url":null,"abstract":"<div><p>The Organ Preservation in patients with Rectal Adenocarcinoma (OPRA) trial is a randomized, non-blinded, phase II prospective study that investigated total neoadjuvant therapy (TNT) and a selective “watch-and-wait” (WW) approach in locally advanced rectal cancer (LARC). It compared two TNT regimens: induction chemotherapy-chemoradiotherapy (INCT-CRT) and chemoradiotherapy-consolidation chemotherapy (CRT-CNCT). Depending on tumor response, patients were offered WW or surgery. The primary endpoint was disease-free survival (DFS), hypothesizing that patients who underwent TNT with selective WW would have improved DFS compared to historical rates. Secondary endpoints included organ preservation (OP) and overall survival, hypothesizing that differences between INCT-CRT and CRT-CNCT could indicate a superior regimen. Results demonstrated treatment of LARC with TNT and selective WW allows for OP in approximately half of patients without negatively impacting oncologic outcomes such as DFS. The data show that a CRT-CNCT regimen had higher rates of OP, lower rates of tumor regrowth, and similar DFS compared to INCT-CRT. Lastly, DFS does not differ between patients who undergo immediate TME versus TME after regrowth. Thus, patients treated with TNT who achieve a clinical complete response (cCR) can safely undergo WW with the potential for OP. Current research to improve TNT and enhance cCR will expand the utility of the WW approach, including the intensification of neoadjuvant chemotherapy (Janus trial), comparing short-course and long-course CRT prior to CNCT (ENSEMBLE and German trials), utilizing fluoropyrimidine-chemotherapy with and without oxaliplatin in the context of WW (CHOW trial), and exploring less invasive operative approaches for early-stage tumors (NEO and NEO-RT trials).</p></div><div><h3>Synopsis</h3><p>The OPRA trial demonstrates treatment of locally advanced rectal cancer using total neoadjuvant therapy with selective “watch-and-wait” allows organ preservation in approximately half of patients without negatively impacting oncologic outcomes. For widespread adoption of “watch-and-wait”, data from accruing prospective trials are needed to demonstrate its viability across diverse clinical settings.</p></div>","PeriodicalId":101191,"journal":{"name":"Surgical Oncology Insight","volume":"1 2","pages":"Article 100043"},"PeriodicalIF":0.0,"publicationDate":"2024-03-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2950247024000525/pdfft?md5=31a05d5057285e38e3e37e8b6861776d&pid=1-s2.0-S2950247024000525-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140400957","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The association between social vulnerability and oncologic stage and treatment in the United States","authors":"Christina M. Stuart ,&nbsp;Adam R. Dyas ,&nbsp;Michael R. Bronsert ,&nbsp;Catherine G. Velopulos ,&nbsp;William G. Henderson ,&nbsp;Richard D. Schulick ,&nbsp;Robert A. Meguid","doi":"10.1016/j.soi.2024.100044","DOIUrl":"https://doi.org/10.1016/j.soi.2024.100044","url":null,"abstract":"<div><h3>Objective</h3><p>Growing evidence supports the impact of sociodemographics on cancer outcomes. The objective of this study was to examine the Social Vulnerability Index (SVI) and its association with oncologic presentation and subsequent treatments across 8 major cancers.</p></div><div><h3>Methods</h3><p>This was a retrospective-cohort study using one institution’s contribution to the National Cancer Database (2011–2021). Patients were grouped into low SVI (&lt;75th percentile) and high SVI (≥75th percentile) cohorts. Un-adjusted comparison between groups was performed followed by multivariable regression to control for the effect of demographic characteristics on oncologic presentation, and for demographic and oncologic characteristics on subsequent treatments. A subgroup analysis was performed comparing cancers that have national screening protocols versus those without.</p></div><div><h3>Results</h3><p>Of 12,712 cases, 2842 (22.4%) were in the high SVI group and 9870 (77.6%). After risk-adjustment, high SVI patients presented at more advanced T-stage (odds ratio 1.09, 95% confidence interval 1.00–1.19); N-stage (1.11, 1.01–1.23); M stage (1.16, 1.03–1.30); and overall stage (1.14, 1.04–1.24) and were more frequently not recommended for surgery (1.15, 1.01–1.32) or chemotherapy (1.20, 1.07–1.38). Screening protocols tended to increase the association between high SVI and advanced oncologic presentation. After adjustment high SVI remained significantly associated with decreased odds of survival (0.85, 0.79 - 0.91).</p></div><div><h3>Conclusions</h3><p>High SVI is associated with advanced stage presentation and decreased likelihood of being recommended surgery or chemotherapy even after risk-adjustment. Differences in presentation stage are predominantly driven by cancers with screening protocols and ultimately high SVI is associated with decreased odds of survival.</p></div>","PeriodicalId":101191,"journal":{"name":"Surgical Oncology Insight","volume":"1 2","pages":"Article 100044"},"PeriodicalIF":0.0,"publicationDate":"2024-03-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2950247024000537/pdfft?md5=bff9198643f9805869c300d2376e128c&pid=1-s2.0-S2950247024000537-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140342410","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multivisceral resection morbidity for left pancreas cancer","authors":"Savana Kuhn ,&nbsp;Kate Vawter ,&nbsp;Allison Wells ,&nbsp;Hanna Jensen ,&nbsp;Judy Bennett ,&nbsp;Emmanouil Giorgakis ,&nbsp;Michail N. Mavros","doi":"10.1016/j.soi.2024.100041","DOIUrl":"https://doi.org/10.1016/j.soi.2024.100041","url":null,"abstract":"<div><h3>Objectives</h3><p>We sought to define the attributable morbidity of multivisceral resection (MVR) during distal/subtotal pancreatectomy (DP) in patients with pancreatic ductal adenocarcinoma (PDAC).</p></div><div><h3>Methods</h3><p>This retrospective review of patients with PDAC used the 2014–2019 pancreas-targeted American College of Surgeons National Surgical Quality Improvement Program database. Operations DP versus MVR were compared based on demographics, comorbidities, intraoperative variables, and postoperative outcomes. Univariate and multivariable logistic regression models assessed morbidity and mortality.</p></div><div><h3>Results</h3><p>Of 3353 distal pancreatectomies, 124 (4%) were MVR. MVR patients were more likely male (56% versus 49%) and smokers (24% versus 18%) but less likely obese (18% versus 29%) or diabetic (21% versus 30%). MVR operations were longer (median 4.3 versus 3.8 h) and involved partial colectomy (100%), gastrectomy (28%), adrenalectomy (20%), and enterectomy (13%). MVR patients had higher unadjusted rates of mortality (2.4% versus 1.1%), serious morbidity (30.7% versus 14.1%), and overall morbidity (61% versus 36%). MVR patients had higher adjusted risk for serious morbidity [odds ratio (OR) 2.13, 95% confidence intervals: 1.28–3.43] and infectious complications [OR 2.75 (1.73–4.31)], but not mortality [OR 1.05 (0.04–3.73)], although the mortality analyses were underpowered.</p></div><div><h3>Conclusions</h3><p>Concurrent MVR during DP doubled the risk of postoperative complications. This should be considered during the sequencing of cancer-directed care and preoperative planning.</p></div>","PeriodicalId":101191,"journal":{"name":"Surgical Oncology Insight","volume":"1 2","pages":"Article 100041"},"PeriodicalIF":0.0,"publicationDate":"2024-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2950247024000501/pdfft?md5=a73b58c30547f70f195b31639dd06536&pid=1-s2.0-S2950247024000501-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140327742","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Factors associated with unplanned readmissions in pediatric surgical oncology patients","authors":"Kathleen Doyle ,&nbsp;Christina M. Theodorou ,&nbsp;Julianne J.P. Cooley ,&nbsp;Theresa H. Keegan ,&nbsp;Erin G. Brown","doi":"10.1016/j.soi.2024.100040","DOIUrl":"https://doi.org/10.1016/j.soi.2024.100040","url":null,"abstract":"<div><h3>Purpose</h3><p>Pediatric oncology patients are at increased risk of unplanned readmissions, but factors associated with readmissions are largely unknown. We aimed to identify patients at increased risk for readmission and characterize unplanned readmissions for pediatric surgical oncology patients.</p></div><div><h3>Methods</h3><p>Patients &lt; 20 years with a first primary solid organ cancer who underwent definitive oncologic surgery from 2005–2017 were identified in the California Cancer Registry linked to statewide hospitalization data. Unplanned 30-day readmissions from their definitive surgery were defined as acute medical problems and/or surgical complications not related to planned admissions for chemotherapy, radiation, or rehabilitation. Multivariable logistic regression identified factors associated with unplanned 30-day readmission.</p></div><div><h3>Results</h3><p>2507 pediatric oncology patients were identified. Median age was 10 years. 49.2% had a 30-day readmission (n = 1233), and 36.7% (n = 452) of these readmissions were unplanned. In multivariable models, those at highest risk of unplanned readmission were &lt; 1 year old (OR 2.72, CI 1.72–4.29) and 1–5 years (OR 1.64, CI 1.20–2.24) vs. ages 13–19; had metastatic disease at diagnosis (OR 1.6, CI 1.1–2.1); and had central nervous system (CNS) tumors (OR 2.5, CI 1.6–3.9), hepatic tumors (OR 2.3, 95% CI 1.2–4.2), or soft tissue/extraosseous sarcomas (OR 2.2, CI 1.3–3.9). Longer initial hospitalizations were associated with a higher likelihood of unplanned readmission (10 days vs. 7 days, p &lt; 0.0001).</p></div><div><h3>Conclusion</h3><p>Unplanned readmissions after surgery for pediatric oncology patients are prevalent. Younger children and those with more advanced/complex disease are at highest risk of unplanned readmissions. Interventions should focus on preventing readmissions in these patients, specifically.</p></div>","PeriodicalId":101191,"journal":{"name":"Surgical Oncology Insight","volume":"1 2","pages":"Article 100040"},"PeriodicalIF":0.0,"publicationDate":"2024-03-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2950247024000495/pdfft?md5=4e0170c76158d6eec8c08a4b06790683&pid=1-s2.0-S2950247024000495-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140122503","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Surgical approach to splenic flexure adenocarcinoma of the colon: Less is more?","authors":"Julia Kohn ,&nbsp;Julia Frebault ,&nbsp;Qi Wang ,&nbsp;Sonja Boatman ,&nbsp;Alexander Troester ,&nbsp;Christine Jensen ,&nbsp;Schelomo Marmor ,&nbsp;Wolfgang B. Gaertner ,&nbsp;Imran Hassan ,&nbsp;Paolo Goffredo","doi":"10.1016/j.soi.2024.100039","DOIUrl":"https://doi.org/10.1016/j.soi.2024.100039","url":null,"abstract":"<div><h3>Introduction</h3><p>Due to the watershed vasculature and lymphatic drainage of splenic flexure (SF) neoplasms, and their exclusion from large clinical trials, optimal management remains debated. This study evaluated extent of resection and surgical approach for SF adenocarcinoma and their respective outcomes.</p></div><div><h3>Methods</h3><p>Adults with stage I-III splenic flexure adenocarcinoma were identified in the National Cancer Database (2004–2020) and categorized by surgical management.</p></div><div><h3>Results</h3><p>Of 7412 patients, 4264 (58%) underwent extended colectomy (EC). The cohorts were overall similar, though more patients with stage I disease were managed with segmental colectomy (SC) (24% <em>vs.</em> 20%, p &lt; 0.01). Those undergoing EC had longer hospital stays (LOS) and greater odds of readmission. Use of robotic-assisted surgery was higher in SC (9% <em>vs.</em> 7%, p &lt; 0.01) and increased from 1% in 2010 to 24% in 2020. This approach was independently associated with a shorter LOS than open surgery. Despite a higher number of lymph nodes examined (median 18 <em>vs.</em> 16), EC and SC had similar nodal (both 37%, p = 0.95) and margin involvement (both 4%, p = 0.39). Five-year survival after EC and SC was similar (75% <em>vs.</em> 76%, p = 0.6). Patients undergoing robotic surgery had significantly lower odds of positive surgical margins and experienced an improved prognosis.</p></div><div><h3>Conclusions</h3><p>EC and SC were performed at similar rates for SF adenocarcinoma, while the use of robotic surgery increased over time. Neither extent of resection nor surgical approach significantly impacted oncologic outcomes. These data indicate that surgical decision-making should be balanced between tumor- and patient-specific considerations, morbidity of extended colectomy, and surgeon preference.</p></div><div><h3>Synopsis</h3><p>In a national cohort of splenic flexure cancers, segmental and extended colectomy were associated with comparable rates of negative margins, nodal involvement, and survival. Robotic assist increased over time without impacting oncologic outcomes. Surgical procedure and approach should thus be tailored to clinical condition and surgeon preference.</p></div>","PeriodicalId":101191,"journal":{"name":"Surgical Oncology Insight","volume":"1 2","pages":"Article 100039"},"PeriodicalIF":0.0,"publicationDate":"2024-03-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2950247024000483/pdfft?md5=d46c68fb981bdfa682b015c20a279c6d&pid=1-s2.0-S2950247024000483-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140122502","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Accuracy of clinical staging for intramural (T2) gastric cancer: Survival outcomes following upfront surgical resection compared to risk of overtreatment with neoadjuvant therapy","authors":"Nazanin Khajoueinejad ,&nbsp;Sayed Imtiaz ,&nbsp;Yael Berger ,&nbsp;Deepti Mahajan ,&nbsp;Demetrius Durham ,&nbsp;Noah A. Cohen ,&nbsp;Daniel M. Labow ,&nbsp;Umut Sarpel ,&nbsp;Benjamin J. Golas ,&nbsp;Hideo Takahashi ,&nbsp;Camilo Correa-Gallego ,&nbsp;Ganesh Gunasekaran ,&nbsp;Spiros P. Hiotis","doi":"10.1016/j.soi.2024.100038","DOIUrl":"10.1016/j.soi.2024.100038","url":null,"abstract":"<div><h3>Background</h3><p>Currently, patients with T1 gastric cancers undergo upfront resection while those with loco-regional disease often are recommended for systemic therapy. Over-staging by endoscopic ultrasound (EUS), specifically in T2 disease, introduces the risk of overtreatment with chemotherapy without the benefit of a confirmed pathological stage. This risk of overtreatment compared to the risk of recurrence after upfront surgery must be weighed in this group.</p></div><div><h3>Methods</h3><p>We retrospectively reviewed patients with gastric cancer who underwent upfront resection between 2010–2020 at our institution. Patients were excluded if they received preoperative systemic therapy or radiation. EUS clinical staging and pathological staging were reconciled for accuracy. Recurrence-free survival and overall survival was calculated for the T2 intramural group. Survival was confirmed by chart review and utilization of the Social Security Death Index.</p></div><div><h3>Results</h3><p>134 patients were included. EUS over-staged 20/37 (54%) of patients defined as having clinical T2 (cT2). Lymph node involvement (cN+) as determined by EUS without biopsy was accurate in 1/9 (11%) when compared to final pathology. In total, 22 cases were confirmed as intramural disease (T2) on final pathology. Six patients with T2 disease (18%) experienced recurrence. With a median follow-up of 32 months, no patients experienced mortality at five years.</p></div><div><h3>Conclusions</h3><p>Clinical staging by EUS introduces the risk of over-staging for patients with T2 gastric cancer. Upfront surgery for these individuals demonstrated encouraging recurrence-free and overall survival. Patients with cT2 gastric cancers should be selectively evaluated for benefits of upfront resection, given risk of over-treated without a survival benefit.</p></div><div><h3>Synopsis</h3><p>Clinical over-staging with endoscopic ultrasound introduces the risk of overtreatment with systemic chemotherapy especially in patients with T2 disease. In this retrospective review, we report the accuracy of EUS in patients with pT2 gastric cancer who underwent upfront resection as well as the recurrence and survival outcomes.</p></div>","PeriodicalId":101191,"journal":{"name":"Surgical Oncology Insight","volume":"1 2","pages":"Article 100038"},"PeriodicalIF":0.0,"publicationDate":"2024-03-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2950247024000471/pdfft?md5=c01e59191343883a547bf2e805856497&pid=1-s2.0-S2950247024000471-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140086916","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical impact of semi-annual mammography in patients undergoing breast conserving surgery following neoadjuvant therapy","authors":"Ton Wang,&nbsp;Christina Weed,&nbsp;Joshua Tseng,&nbsp;Alice Chung,&nbsp;Alison Moody,&nbsp;Sara Grossi,&nbsp;Marissa K. Boyle,&nbsp;Armando E. Giuliano,&nbsp;Farin Amersi","doi":"10.1016/j.soi.2024.100037","DOIUrl":"10.1016/j.soi.2024.100037","url":null,"abstract":"<div><h3>Introduction</h3><p>Guidelines recommend annual mammography for most patients following breast conserving surgery (BCS) for invasive breast cancer (IBC). However, for patients treated with BCS following neoadjuvant therapy (NAT), the optimal frequency for surveillance has not been established. The study objective is to assess the efficacy of semi-annual mammography after BCS in patients treated with NAT.</p></div><div><h3>Methods</h3><p>An institutional database of patients with IBC (cT1-T4, N0-N3, M0) who received BCS following NAT from 2007–2020 was analyzed. Clinicopathologic features, surveillance imaging, and outcomes were analyzed. Direct costs associated with surveillance were estimated based on Medicare Physician Fees.</p></div><div><h3>Results</h3><p>139 patients received BCS following NAT, of which 59 (42.4%) had a pathologic complete response. Most patients received semi-annual mammography for 24 months post-operatively (84.2%, 82.0%, 80.0%, and 78.0% of patients received a mammogram at 6, 12, 18, and 24 months, respectively). Biopsies were performed due to abnormal imaging findings in 9 (6.5%), 7 (5.3%), 2 (1.5%), and 8 (6.3%) patients at 6, 12, 18, and 24 months, respectively. Overall, 77.8% of biopsies performed were benign. At median follow up of 65 months (IQR 37–86), 22 (15.8%) patients developed recurrences, of which 14 (63.6%) were distant and 8 (36.4%) were locoregional. Only 2 (1.4%) patients had a recurrence detected by mammographic surveillance. The additional direct costs associated with semi-annual imaging was $373.68 per patient.</p></div><div><h3>Conclusions</h3><p>There is insufficient evidence to support semi-annual mammography in the early post-operative period following BCS in patients treated with NAT, and annual mammography with clinical exam is likely sufficient.</p></div><div><h3>Synopsis</h3><p>To date, there is no consensus on the optimal frequency of mammographic surveillance in breast cancer patients receiving breast conserving surgery following neoadjuvant therapy given their higher risk for recurrent disease. Our data demonstrates overall low-yield and high costs associated with semi-annual mammography and suggests that annual mammography with clinical breast exam is sufficient for detecting locoregional recurrences.</p></div>","PeriodicalId":101191,"journal":{"name":"Surgical Oncology Insight","volume":"1 2","pages":"Article 100037"},"PeriodicalIF":0.0,"publicationDate":"2024-03-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S295024702400046X/pdfft?md5=b647a33e6f1b1d44628b4a44765c1032&pid=1-s2.0-S295024702400046X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140088744","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}